AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Canavan Disease

Recent research efforts aimed at curing Canavan Disease.

Last updated

Canavan Disease

Overview

Canavan disease is a rare inherited disorder in which both copies of the ASPA gene do not work properly. This prevents production of enough aspartoacylase, an enzyme needed to break down N-acetylaspartate (NAA), a brain chemical that becomes abnormally high and is associated with damage to white matter and myelin, the insulating material that helps nerve cells communicate. The most common “typical” form begins in infancy, usually with poor head control, low muscle tone, developmental delay, enlarging head size, feeding difficulties, and later loss of skills; less common atypical forms can begin later and progress more slowly. Canavan disease is inherited in an autosomal-recessive pattern and shortens life expectancy, although severity varies substantially. GeneReviews: Canavan Disease

There is no approved cure or disease-modifying treatment. Current care is supportive and multidisciplinary: treatment of seizures and spasticity, physical and occupational therapy, feeding and swallowing support, management of aspiration and respiratory risks, adaptive equipment, and family-centered palliative and social support. GeneReviews: Canavan Disease

Scope of Recent Research (2020–present)

Research since 2020 has become more clinically focused, with two separate adeno-associated virus (AAV) gene-replacement programs in phase 1/2 studies and several preclinical strategies designed either to restore ASPA or reduce NAA production. The field remains very small because Canavan disease is ultra-rare, but the emergence of measurable biological improvements—especially lower NAA and improved myelin-related MRI measures—means it is closer to a potential disease-modifying therapy than it was at the beginning of the decade; however, no approach has yet demonstrated that it can permanently cure the disease. Oligodendrocyte-targeted AAV trial GeneReviews: Canavan Disease

Major Breakthroughs and Emerging Therapies

The leading strategy is gene replacement: delivering a working ASPA gene using AAV, a modified, non-replicating viral delivery vehicle. The strongest published clinical evidence comes from MYR-101, which uses an AAV capsid called Olig001 that preferentially enters oligodendrocytes—the brain cells central to myelin production. In an interim phase 1/2 analysis of eight children who received a single intracranial dose, cerebrospinal-fluid NAA declined, total brain myelin increased, and developmental scores improved over 12 months. Serious adverse events occurred in seven participants, but investigators judged none to be related to MYR-101, and all reported adverse events resolved. These early, uncontrolled results are encouraging but cannot yet establish long-term benefit or a cure. Oligodendrocyte-targeted AAV trial

A second gene-replacement approach, BBP-812, uses AAV9 delivered intravenously to carry an optimized human ASPA gene to the central nervous system and other tissues. The CANaspire study is testing whether systemic administration can avoid neurosurgery while producing sufficient enzyme in the brain. The study remains a phase 1/2 trial, so its main purpose is to establish safety, tolerability, and biological activity rather than prove clinical efficacy. CANaspire trial record

A third direction aims not to replace the missing enzyme but to lower the amount of its toxic substrate. Researchers have used antisense oligonucleotides—short synthetic strands of nucleic acid that reduce expression of a chosen gene—to suppress NAT8L, the neuronal gene that makes NAA. In symptomatic Canavan mouse models, lowering Nat8l expression reduced brain NAA and reversed ataxia, cerebellar-cell abnormalities, and brain vacuolation. NAT8L antisense therapy in mice A related dual-function AAV therapy combined ASPA replacement with Nat8l silencing; it reversed substantial established pathology in moderately advanced mice, but treatment at a very late disease stage produced neurological worsening despite improvements in some laboratory and imaging measures. Dual-function AAV therapy in mice

Cell therapy remains experimental. A 2022 study corrected patient-derived induced pluripotent stem cells (iPSCs)—adult cells reprogrammed into stem-cell-like cells—with a normal ASPA gene, converted them into neural progenitor cells, and transplanted them into Canavan mice. The transplanted cells restored ASPA activity, lowered NAA in brain and cerebrospinal fluid, improved myelination and motor performance, and reduced spongy degeneration in the model. Corrected iPSC therapy in mice This strategy could potentially supply both enzyme-producing cells and cells capable of supporting myelin, but it has not entered a human efficacy trial.

Clinical Trials and Experimental Approaches

MYR-101 is being studied in the open-label phase 1/2 CAN-GT trial, sponsored by Myrtelle. The intervention is delivered into the cerebrospinal-fluid space through an intracerebroventricular neurosurgical procedure and is designed to target oligodendrocytes directly. The published 12-month interim analysis included eight treated children and reported lower cerebrospinal-fluid NAA, greater myelination, and improved Mullen Scales of Early Learning outcomes; the investigators emphasized that the findings are preliminary. Oligodendrocyte-targeted AAV trial The trial is listed as active but not recruiting in the current clinical summary. GeneReviews: Canavan Disease

CANaspire (NCT04998396), sponsored by Aspa Therapeutics, a BridgeBio subsidiary, is a recruiting phase 1/2 open-label study of intravenous BBP-812 in children from birth through 30 months of age. It combines systemic AAV9-ASPA delivery with prednisolone, a corticosteroid used to manage immune responses. As of the September 12, 2026 registry update, the study was recruiting; formal peer-reviewed clinical outcomes have not yet been published. CANaspire trial record

A separate single-patient expanded-access study tested combined intravenous and intracerebroventricular AAV9-ASPA administration with immune modulation. The 2023 report described sustained reductions in cerebrospinal-fluid NAA and improvements in selected MRI-based measures through follow-up, but evidence from one treated individual cannot establish safety or effectiveness for the wider Canavan population. Dual-route AAV9 expanded-access report

Methodologies and Scientific Approaches

Canavan researchers use mouse models lacking functional aspartoacylase, patient-derived iPSCs, and clinical natural-history cohorts to test treatments and determine which outcomes best reflect meaningful change. Key biomarkers include NAA in urine, cerebrospinal fluid, and brain magnetic resonance spectroscopy; MRI measures of white matter, myelin, and extracellular water; and developmental or motor assessments such as the Gross Motor Function Measure and Mullen Scales of Early Learning. Oligodendrocyte-targeted AAV trial Urine NAA phenotype biomarker study

The main delivery-platform question is whether treatment should be given directly to the brain or through the bloodstream. Intracerebroventricular AAV can use a lower vector dose and preferentially reach relevant brain cells, but requires neurosurgery; intravenous AAV9 is less invasive and may reach the brain more broadly, but requires careful management of systemic exposure and immune responses. Researchers are also testing combination approaches that both restore ASPA and reduce NAA synthesis, reflecting evidence that accumulated NAA is important but may not explain every aspect of the disease. Oligodendrocyte-targeted AAV trial Dual-function AAV therapy in mice

Leading Institutions and Funding

Myrtelle, Dayton Children’s Hospital, Rowan University, the University of Cincinnati, and Wright State University contributed to the MYR-101 clinical program and its 2025 publication. Oligodendrocyte-targeted AAV trial Aspa Therapeutics and collaborating clinical centers are leading the systemic BBP-812 program and its associated CANinform natural-history study, which has helped establish NAA and motor-development measures for evaluating treatment effects. Urine NAA phenotype biomarker study

City of Hope’s Beckman Research Institute has been a major center for the iPSC-based cell-therapy approach. The California Institute for Regenerative Medicine awarded the group $7,377,384 for process development toward an iPSC-based Canavan therapeutic candidate, including manufacturing methods compatible with clinical-grade production. CIRM iPSC process-development award NIH-supported work at the University of California, Davis has also advanced NAA-focused approaches, including efforts to manipulate NAA transport through the NaDC3 transporter. NIH RePORTER: NAA transport project

Strengths, Limitations, and Challenges

The central strength of current research is that therapies are aimed directly at disease biology: either restore ASPA activity, lower NAA, or both. The MYR-101 study provides the first peer-reviewed evidence in children that a targeted gene therapy can change biochemical, imaging, and early developmental measures together. Oligodendrocyte-targeted AAV trial The availability of natural-history data and quantitative biomarkers should also make future trials more interpretable in a disorder where randomized placebo-controlled studies may be difficult. Urine NAA phenotype biomarker study

Important limitations remain. Trials are small, open-label, and use short interim follow-up, so apparent developmental gains could be affected by baseline differences, assessment limitations, or the natural variability of rare disease. AAV gene therapy may face immune barriers, challenges in delivering enough treatment to the right brain cells, and uncertainty about durability in a growing child. Direct brain delivery adds surgical burden, whereas systemic delivery raises questions about dose, organ exposure, and pre-existing antibodies to AAV. The preclinical dual-function study also suggests that there may be a point beyond which damaged brain tissue is harder to rescue, reinforcing the likely importance of very early diagnosis and intervention. Dual-function AAV therapy in mice Cell therapy must still address manufacturing consistency, graft safety, surgical delivery, and proof of benefit in humans. CIRM iPSC process-development award

Outlook and Future Directions

As of October 11, 2026, Canavan disease does not have a cure, but the field has reached a meaningful transition: two distinct ASPA gene-replacement strategies are in phase 1/2 clinical development, and one has published early evidence of biological and developmental benefit. The most important milestones to watch are longer-term MYR-101 follow-up; peer-reviewed results from CANaspire; confirmation that treatment benefit is greatest when delivered early; validation of NAA, MRI, and functional endpoints across patients; and whether NAA-lowering RNA or small-molecule approaches can safely complement gene replacement. GeneReviews: Canavan Disease Oligodendrocyte-targeted AAV trial

References

Don't see your disease? Request a report